Abstract
Recently, sandwich-cultured (SC) rat hepatocytes have been used as an in vitro model to assess biliary excretion of drugs and xenobiotics. The purpose of the present study was to validate the use of SC rat hepatocytes for the in vitro assessment of P-glycoprotein (P-gp)-mediated biliary drug excretion. The specific and fluorescent P-gp substrate rhodamine 123 (Rh123) and the P-gp substrate digoxin were selected as model compounds. Rh123 and digoxin accumulation and Rh123 efflux under standard and Ca2+-free conditions were quantified in SC rat hepatocytes to determine substrate secretion into canalicular networks in vitro. The major role of P-gp in the biliary excretion of these compounds was confirmed by inhibition experiments with the potent P-gp inhibitor GF120918. Hepatocyte culture conditions, including media type and time in culture, significantly affected Rh123 biliary excretion. P-gp expression, as assessed by Western blot, was increased with culture time. Dexamethasone (an in vivo inducer of P-gp) concentrations ranging from 0.01 to 1 μM in the cell culture medium did not influence P-gp expression or Rh123 biliary excretion. Rh123 and digoxin biliary clearance values, predicted from SC rat hepatocyte data, were consistent with values reported in vivo and in isolated perfused rat liver studies. In conclusion, the results of this study demonstrate the utility of SC rat hepatocytes as an in vitro model to study and predict the biliary excretion of P-gp substrates.
Footnotes
-
This study was supported by National Institutes of Health Grant GM41935.
- Abbreviations used are::
- IPRL
- isolated perfused rat liver
- SC
- sandwich-cultured
- P-gp
- P-glycoprotein
- Rh123
- rhodamine 123
- DMEM
- Dulbecco's modified Eagle's medium
- WEM
- Williams' E medium
- MCM
- modified Chee's medium
- BSA
- bovine serum albumin
- FBS
- fetal bovine serum
- ITS
- insulin-transferrin-selenium supplement
- HBSS
- Hanks' balanced salt solution
- BEI
- biliary excretion index
- MDR
- multidrug resistance
- Received January 2, 2001.
- Accepted June 19, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|